NLRP3 — Drug Target

All drugs that target NLRP3 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

NLRP3 inflammasome inhibitor

Phase 3 pipeline (2)

• BMS-986278 · Bristol-Myers Squibb · NLRP3 inflammasome inhibitor · Immunology
  BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.
• BMS-986205 · Bristol-Myers Squibb · NLRP3 inflammasome inhibitor · Immunology
  BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.

Phase 2 pipeline (2)

• ASP1517 · Astellas Pharma Inc · NLRP3 inflammasome inhibitor · Inflammation
  ASP1517 is a selective and potent inhibitor of the NLRP3 inflammasome.
• AQX-1125 · Aquinox Pharmaceuticals (Canada) Inc. · NLRP3 inflammasome inhibitor · Rheumatology
  AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome.